Development
Acrivon Therapeutics, Inc.
ACRV
$1.35
$0.108.00%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -50.07M | -44.80M | -36.70M | -31.17M | -26.58M |
| Total Depreciation and Amortization | 512.00K | 495.00K | 444.00K | 364.00K | 252.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.82M | 5.40M | 3.70M | 2.22M | 1.46M |
| Change in Net Operating Assets | 2.11M | 2.56M | -501.00K | -1.53M | 476.00K |
| Cash from Operations | -39.63M | -36.34M | -33.06M | -30.12M | -24.39M |
| Capital Expenditure | -388.00K | -814.00K | -1.78M | -2.17M | -2.05M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -64.50M | -110.71M | -130.16M | -139.51M | -44.69M |
| Cash from Investing | -64.89M | -111.52M | -131.93M | -141.68M | -46.75M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 104.92M | 104.86M | 104.48M | 104.48M | 24.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | 99.75M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.60M | -2.76M | -2.77M | -2.77M | -175.00K |
| Cash from Financing | 102.32M | 102.10M | 101.71M | 101.71M | 99.60M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.20M | -45.77M | -63.28M | -70.08M | 28.47M |